,12,13 For example, engineered high-affinity, soluble TCRs specific to the melanoma-associated antigen gp100 or the more widely cancer-associated NY-ESO1 peptides have demonstrated success in preclinical models and clinical trials with respect to specificity and potency.8 This evidence concerns the gene PMEL and melanoma.